Donald E Kohan1. 1. Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA. donald.kohan@hsc.utah.edu
Abstract
PURPOSE OF REVIEW: Endothelin is important in the development of cardiorenal disease. This review discusses recent developments in understanding endothelin's role in hypertension and chronic kidney disease (CKD). RECENT FINDINGS: Endothelin-1 production is increased in hypertension and CKD. Endothelin-1 stimulates vasoconstriction, inflammation and fibrosis, thereby promoting hypertension, atherosclerosis and CKD. These effects are closely linked to angiotensin II and reactive oxygen species. In preclinical studies, endothelin receptor antagonists were effective in treating hypertension (particularly with endothelial dysfunction) and CKD. In preclinical studies, endothelin A-selective, as opposed to combined endothelin A and B, receptor blockers have generally been more efficacious. Few clinical trials have been conducted in hypertension and/or kidney disease, partly due to concerns over side effects of testicular toxicity and fluid retention. Endothelin blockade reduces blood pressure in patients with resistant hypertension, with additional beneficial metabolic effects. Endothelin antagonism improves proteinuria in CKD (diabetic or not), particularly in patients taking inhibitors of angiotensin II action. SUMMARY: Endothelin is a promising target in the treatment of resistant hypertension and CKD, with additional potential benefits on atherosclerosis and the metabolic syndrome. The nature and mechanisms of drug side effects require elucidation before the potential of this new class of drugs can be fully realized.
PURPOSE OF REVIEW: Endothelin is important in the development of cardiorenal disease. This review discusses recent developments in understanding endothelin's role in hypertension and chronic kidney disease (CKD). RECENT FINDINGS:Endothelin-1 production is increased in hypertension and CKD. Endothelin-1 stimulates vasoconstriction, inflammation and fibrosis, thereby promoting hypertension, atherosclerosis and CKD. These effects are closely linked to angiotensin II and reactive oxygen species. In preclinical studies, endothelin receptor antagonists were effective in treating hypertension (particularly with endothelial dysfunction) and CKD. In preclinical studies, endothelin A-selective, as opposed to combined endothelin A and B, receptor blockers have generally been more efficacious. Few clinical trials have been conducted in hypertension and/or kidney disease, partly due to concerns over side effects of testicular toxicity and fluid retention. Endothelin blockade reduces blood pressure in patients with resistant hypertension, with additional beneficial metabolic effects. Endothelin antagonism improves proteinuria in CKD (diabetic or not), particularly in patients taking inhibitors of angiotensin II action. SUMMARY: Endothelin is a promising target in the treatment of resistant hypertension and CKD, with additional potential benefits on atherosclerosis and the metabolic syndrome. The nature and mechanisms of drug side effects require elucidation before the potential of this new class of drugs can be fully realized.
Authors: Yuqiang Ge; Alan Bagnall; Peter K Stricklett; Kevin Strait; David J Webb; Yuri Kotelevtsev; Donald E Kohan Journal: Am J Physiol Renal Physiol Date: 2006-07-25
Authors: Gary P Van Guilder; Christian M Westby; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza Journal: Hypertension Date: 2007-06-18 Impact factor: 10.190
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: Denisha Spires; Bibek Poudel; Corbin A Shields; Alyssa Pennington; Brianca Fizer; Lateia Taylor; Kasi C McPherson; Denise C Cornelius; Jan M Williams Journal: Am J Physiol Renal Physiol Date: 2018-05-30
Authors: Cissy Chenyi Zhou; Roxanna A Irani; Yingbo Dai; Sean C Blackwell; M John Hicks; Susan M Ramin; Rodney E Kellems; Yang Xia Journal: J Immunol Date: 2011-04-11 Impact factor: 5.422
Authors: Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid Journal: J Sex Med Date: 2014-12-11 Impact factor: 3.802
Authors: Weiru Zhang; Yujin Zhang; Wei Wang; Yingbo Dai; Chen Ning; Renna Luo; Kaiqi Sun; Louise Glover; Almut Grenz; Hong Sun; Lijian Tao; Wenzheng Zhang; Sean P Colgan; Michael R Blackburn; Holger K Eltzschig; Rodney E Kellems; Yang Xia Journal: Circ Res Date: 2013-04-12 Impact factor: 17.367